India Molecular Diagnostics Market To Reach $1,717.27 Million By 2033

November 2025 | Report Format: Electronic (PDF)

India Molecular Diagnostics Market Growth & Trends

The India molecular diagnostics market size is expected to reach USD 1,717.27 million by 2033, registering a CAGR of 5.63% from 2025 to 2033, according to a new report by Grand View Research, Inc. The growth is attributed to the rising aging population, growing prevalence of target disease, increase in demand for point-of-care facilities, and technological advancement in diagnostic products.

In India, the prevalence of infectious and vector-borne diseases is high. This includes diseases such as Tuberculosis (TB), H1N1 flu, and vector-borne diseases like malaria and dengue. In addition, CVDs, respiratory infections, diarrhea, and chronic renal diseases further drive the disease burden in the country. According to the NTP report, in 2021, around 4.4 lakh individuals died of TB, which is about 29% of the world's total 1.5 million deaths.

Moreover, the WHO estimated 3 to 5 million cases of severe influenza annually in the country. India also accounts for approximately 4% of the worldwide malaria burden. CVD is another high-prevalence condition in the country, with 54.5 million estimated annual cases, and leads to 4,000 deaths daily. Therefore, the rising burden of such diseases is increasing the demand for diagnostics and fueling the India molecular diagnostics industry.

The market is witnessing rapid technological advancements to obtain low-cost, and highly portable & accurate products. Innovative product launches are also a result of the rising number of R&D and partnership programs. For instance, in August 2022, a UK-based company, Congenica Ltd., partnered with an Indian diagnostic company, Avesthagen Limited, to offer genomic diagnostic services for Avigna Diagnostics business unit, an Indian biotechnology company. This tie-up would reduce diagnostic time by offering a rapid interpretation of NGS data. Similarly, in January 2022, Avesthagen announced a strategic partnership with Wipro, an Indian IT and consulting firm, for the development and commercialization of NGS panels in India.

Amid the COVID-19 pandemic, companies strategically expanded their presence in India by providing cost-effective COVID-19 diagnostic products. For example, in July 2021, Abbott announced the COVID-19 home test kit at a price of around USD 4.07. This increased the product’s target population in the country.

Furthermore, the demand for PoC healthcare facilities is increasing due to government/political support, economic outcomes, rising patient awareness, and advancement in technology. For instance, to curb the gaps in the test-and-treat loop, the Indian government planned to establish POC technology in more than 150,000 government health & wellness centers across the country under the Swasth Bharat, Samridh Bharat initiative. Therefore, such initiatives are boosting the market growth.

key Request a free sample copy or view report summary: India Molecular Diagnostics Market Report

India Molecular Diagnostics Market Report Highlights

The reagents & consumables segment held the largest revenue share of 59.75% in 2024, due to new diagnostic tests, government support, and regulatory approvals. Reagents and consumables, such as kits, probes, enzymes, and sample materials, are fundamental to performing precise and efficient molecular testing.
Based on test location, The Point of Care (POC) test location segment held the largest share of the India molecular diagnostics industry in 2024
Based on technology Polymerase Chain Reaction (PCR) held the largest share of the India molecular diagnostics market in 2024
The respiratory infections segment held the largest share of the India molecular diagnostics industry in 2024. Respiratory infections are a primary cause of morbidity and mortality in the Indian context, particularly in children.

India Molecular Diagnostics Market Segmentation

Grand View Research has segmented the India molecular diagnostics market based on product, application, technology, test location, platform, and end use:

India Molecular Diagnostics Product Outlook (Revenue, USD Million, 2021 - 2033)

Instruments
Reagents and Consumables
Others

India Molecular Diagnostics Test Location Outlook (Revenue, USD Million, 2021 - 2033)

Point of Care
Self-Test or OTC
Central Laboratories

India Molecular Diagnostics Technology Outlook (Revenue, USD Million, 2021 - 2033)

Polymerase Chain Reaction (PCR)
- Multiplex PCR
- Real-Time PCR
- Open PCR
Others

India Molecular Diagnostics Platform Outlook (Revenue, USD Million, 2021 - 2033)

Sample-to-answer
High-throughput Closed Systems
Open PCR / LDT Platforms

India Molecular Diagnostics Application Outlook (Revenue, USD Million, 2021 - 2033)

Gastrointestinal Infections
- Enteric Bacterial
  - Salmonella
  - Shigella
  - Campylobacter
  - E. Coli
  - Others
- Enteric Viral
  - Norovirus
  - Rotavirus
  - Adenovirus
  - Astrovirus
  - Sapovirus
- Enteric Parasitic
  - Giardia Lamblia
  - Cryptosporidium spp.
  - Entamoeba Histolytica
Respiratory Infections
- Viral Respiratory Infections
  - Influenza A & B
  - SARS-CoV-2
  - RSV
  - Human Metapneumovirus
  - Parainfluenza
  - Adenovirus
  - Rhinovirus / Enterovirus
  - Others
- Bacterial Respiratory Infections
  - Mycobacterium Tuberculosis
  - Bordetella Pertussis
  - Mycoplasma Pneumoniae
  - Chlamydophila Pneumoniae
  - Others
Healthcare-Associated Infections

MRSA
Clostridium Difficile
Carbapenemase-Producing Organisms (CPO)
Others

Sexually Transmitted Infections & Women’s Health
- HIV
- Neisseria Gonorrhoeae
- Hepatitis B (HBV)
- Hepatitis C (HCV)
- Trichomonas Vaginalis
- Mycoplasma Genitalium
- HSV
- HPV
- Group B Streptococcus (GBS)
- Chlamydia Trachomatis
- Syphilis
- Others
Others